| Dr William M Young, MD | |
|
725 Glenwood Drive, Suite E 780, Chattanooga, TN 37404 | |
| (423) 697-9972 | |
| (423) 697-1798 |
| Full Name | Dr William M Young |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 29 Years |
| Location | 725 Glenwood Drive, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952308421 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 35014 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Healthcare System, Inc | Chattanooga, TN | Hospital |
| Rhea Medical Center | Dayton, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Health Partners Foundation, Inc | 8022919570 | 303 |
News Archive
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness.
People with prehypertension have a 55 percent higher risk of experiencing a future stroke than people without prehypertension, report researchers at the University of California, San Diego School of Medicine in a new meta-analysis of scientific literature published in the September 28 online issue of the journal Neurology.
One major obstacle in the fight against cancer is that anticancer drugs often affect normal cells in addition to tumor cells, resulting in significant side effects. Yet research into development of less harmful treatments geared toward the targeting of specific cancer-causing mechanisms is hampered by lack of knowledge of the molecular pathways that drive cancers in individual patients.
› Verified 3 days ago
| Entity Name | Memorial Health Partners Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922053545 PECOS PAC ID: 8022919570 Enrollment ID: O20040116000823 |
News Archive
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness.
People with prehypertension have a 55 percent higher risk of experiencing a future stroke than people without prehypertension, report researchers at the University of California, San Diego School of Medicine in a new meta-analysis of scientific literature published in the September 28 online issue of the journal Neurology.
One major obstacle in the fight against cancer is that anticancer drugs often affect normal cells in addition to tumor cells, resulting in significant side effects. Yet research into development of less harmful treatments geared toward the targeting of specific cancer-causing mechanisms is hampered by lack of knowledge of the molecular pathways that drive cancers in individual patients.
› Verified 3 days ago
| Entity Name | Chattanooga Urology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780680348 PECOS PAC ID: 4688686249 Enrollment ID: O20060622000277 |
News Archive
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness.
People with prehypertension have a 55 percent higher risk of experiencing a future stroke than people without prehypertension, report researchers at the University of California, San Diego School of Medicine in a new meta-analysis of scientific literature published in the September 28 online issue of the journal Neurology.
One major obstacle in the fight against cancer is that anticancer drugs often affect normal cells in addition to tumor cells, resulting in significant side effects. Yet research into development of less harmful treatments geared toward the targeting of specific cancer-causing mechanisms is hampered by lack of knowledge of the molecular pathways that drive cancers in individual patients.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William M Young, MD 725 Glenwood Drive, Suite E 780, Chattanooga, TN 37404 Ph: (423) 697-9972 | Dr William M Young, MD 725 Glenwood Drive, Suite E 780, Chattanooga, TN 37404 Ph: (423) 697-9972 |
News Archive
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness.
People with prehypertension have a 55 percent higher risk of experiencing a future stroke than people without prehypertension, report researchers at the University of California, San Diego School of Medicine in a new meta-analysis of scientific literature published in the September 28 online issue of the journal Neurology.
One major obstacle in the fight against cancer is that anticancer drugs often affect normal cells in addition to tumor cells, resulting in significant side effects. Yet research into development of less harmful treatments geared toward the targeting of specific cancer-causing mechanisms is hampered by lack of knowledge of the molecular pathways that drive cancers in individual patients.
› Verified 3 days ago
Dr. Samuel M Currin, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 725 Glenwood Dr, Ste E780, Chattanooga, TN 37404 Phone: 423-697-0072 Fax: 423-697-1798 | |
Dr. Ringland Smith Murray, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1625 Edgewood Lane, Chattanooga, TN 37405 Phone: 423-266-5592 | |
Kymber L Habenicht, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1300 Cleveland Ave, Chattanooga, TN 37404 Phone: 423-756-7860 Fax: 423-756-9137 | |
Dr. Marty Scheinberg, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1300 Cleveland Ave, Chattanooga, TN 37404 Phone: 423-756-7860 | |
Dr. Henry Tobechi Okafor, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 979 E 3rd St Ste C-925, Chattanooga, TN 37403 Phone: 423-778-5910 Fax: 423-778-5915 | |
Dr. David Sahaj, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1300 Cleveland Ave, Chattanooga, TN 37404 Phone: 423-756-7860 | |
Benjamin Tracy Waldorf, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 979 E 3rd St Ste C-925, Chattanooga, TN 37403 Phone: 423-778-5910 Fax: 423-778-5915 |